BioSpace News Archive

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that the Company will report its fourth quarter and full year 2022 financial results and provide a corporate update on Tuesday, March 14, 2023.

PreciseDx today announced that it will present a poster showcasing the development and validation of its AI-enabled hematoxylin and eosin (H&E) image analysis grading and phenotyping Platform to predict risk of early-stage breast cancer recurrence.

Vistagen (NASDAQ: VTGN) today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the Company’s investigational pherine nasal spray for the treatment of major depressive disorder (MDD).

Novan, Inc., announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan.

Acasti Pharma Inc. today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Oppenheimer 33rd Annual Healthcare Conference, held virtually and taking place on March 13-15, 2023.

Hoth Therapeutics, Inc. today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001.

Bayer announced a partnership with French company M2i Group to supply fruit and vegetable growers around the world with pheromone-based biological crop protection products.

A team of researchers from Rowan-Virtua School of Osteopathic Medicine (Rowan-Virtua SOM) and Durin Technologies, Inc., have announced the results of a newly-designed blood test that can detect the presence of Alzheimer’s disease-related pathology up to 10 years before symptoms arise with a nearly 97 percent accuracy rate.

BioCryst Pharmaceuticals, Inc. announced that the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has issued a positive recommendation for ORLADEYO® to be reimbursed for the routine prevention of attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Needham Virtual Neuroscience Forum on Wednesday, March 15, 2023 at 10:00 a.m. ET.